141 related articles for article (PubMed ID: 34047801)
1. Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer.
Evangelista L; Cassarino G; Lauro A; Morlacco A; Sepulcri M; Nguyen AAL; Ietto F; Cecchin D; Lacognata C; Zucchetta P
Abdom Radiol (NY); 2021 Sep; 46(9):4401-4409. PubMed ID: 34047801
[TBL] [Abstract][Full Text] [Related]
2. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
3. Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI.
Achard V; Lamanna G; Denis A; De Perrot T; Mainta IC; Ratib O; Iselin C; Miralbell R; Garibotto V; Zilli T
Med Oncol; 2019 Jun; 36(8):67. PubMed ID: 31190232
[TBL] [Abstract][Full Text] [Related]
4. Value of
García JR; Compte A; Buxeda M; Mourelo S; Soler M; Blanch A; Valls E; Riera E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):197-203. PubMed ID: 32165153
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.
Couñago F; Recio M; Maldonado A; Del Cerro E; Díaz-Gavela AA; Thuissard IJ; Sanz-Rosa D; Marcos FJ; Olaciregui K; Mateo M; Cerezo L
Cancer Imaging; 2016 Dec; 16(1):42. PubMed ID: 27927229
[TBL] [Abstract][Full Text] [Related]
7. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.
Buchegger F; Garibotto V; Zilli T; Allainmat L; Jorcano S; Vees H; Rager O; Steiner C; Zaidi H; Seimbille Y; Ratib O; Miralbell R
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):68-78. PubMed ID: 24104592
[TBL] [Abstract][Full Text] [Related]
8. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
[TBL] [Abstract][Full Text] [Related]
9. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
10. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
[TBL] [Abstract][Full Text] [Related]
11. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.
Triviño-Ibáñez EM; Puche-Sanz I; Gómez-Río M; Cózar Olmo JM; Llamas-Elvira JM; Rodríguez-Fernández A
Med Clin (Barc); 2019 Jul; 153(2):56-62. PubMed ID: 30660434
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
16. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
[TBL] [Abstract][Full Text] [Related]
17. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer.
Pelosi E; Arena V; Skanjeti A; Pirro V; Douroukas A; Pupi A; Mancini M
Radiol Med; 2008 Sep; 113(6):895-904. PubMed ID: 18414809
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
19. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S
World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995
[TBL] [Abstract][Full Text] [Related]
20.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
